Sanofi S.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sanofi S.A. - overview
Established
1973
Location
Paris, -, France
Primary Industry
Pharmaceuticals
About
Based in France, Sanofi S. A. is a pharmaceutical company specializing in research and development of innovative medications and vaccines to address critical health challenges globally. Sanofi S.
A. is a biopharmaceutical company formed in 1973 and headquartered in Paris, France. The company focuses on developing solutions across various therapeutic areas such as immunology, neurology, and oncology. The firm was co-founded by Ahmed Lotfy, Ali Sheibani, Channy Lucienne, Jacques Brom, Jochen Maas, Muhammad Zahid, Paul Hudson, and TJ Roberts.
It has undergone strategic pivots to enhance its R&D capabilities and has expanded its global reach through partnerships and collaborations. Sanofi is a prominent R&D-driven and AI-powered biopharma company that focuses on a wide array of therapeutic areas, including immunology, neurology, oncology, rare blood disorders, rare diseases, and vaccines. Their product offerings encompass innovative medications and vaccines designed to address critical health challenges, improve patient outcomes, and enhance the quality of life for individuals and communities. These products are utilized in various healthcare settings, serving a diverse client base that includes healthcare professionals, hospitals, and outpatient facilities.
Sanofi's vaccines, such as those for influenza and meningococcal meningitis, have been widely distributed in markets across North America, Europe, and Asia-Pacific. The company strives to deliver solutions that meet the evolving needs of patients and healthcare systems globally. In 2023, Sanofi generated revenue of USD 3,258. 01 mn and recorded an EBITDA of USD 120.
15 mn. The company generates revenue through an extensive portfolio of pharmaceutical products and vaccines, engaging in direct sales to healthcare providers and institutions. The company utilizes a multi-faceted transaction structure that includes partnerships with healthcare organizations, direct-to-consumer sales for certain products, and collaborations with wholesalers and retailers for distribution. Flagship products in their lineup drive substantial revenue streams, and strategic pricing models are employed to ensure accessibility and competitiveness in various markets.
Revenue is further supported through research collaborations and licensing agreements within the biopharma sector, allowing for continued innovation and growth. By maintaining a robust pipeline of clinical developments, Sanofi positions itself to capitalize on emerging healthcare opportunities.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.sanofi.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Sanofi S.A. - timeline of key events
Sanofi S.A. - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 30,384,000,000 | 33,389,000,000 | 34,947,000,000 | 32,951,000,000 | 33,770,000,000 | 34,542,000,000 | 33,821,000,000 | 35,055,000,000 | 34,463,000,000 | 36,126,000,000 | 2,939,000,000 | 2,932,000,000 | - | - | - |
| % Revenue Growth (YoY) | - | 9.9% | 4.7% | (5.7%) | 2.5% | 2.3% | (2.1%) | 3.6% | (1.7%) | 4.8% | (91.9%) | (0.2%) | - | - | - |
| EBITDA (USD) | 9,490,000,000 | 9,045,000,000 | 9,628,000,000 | 8,020,000,000 | 8,625,000,000 | 7,761,000,000 | 8,226,000,000 | 7,669,000,000 | 6,846,000,000 | 5,271,000,000 | 790,000,000 | 951,000,000 | - | - | - |
| Operating Income (USD) | 5,961,000,000 | 5,731,000,000 | 6,337,000,000 | 5,106,000,000 | 6,143,000,000 | 5,624,000,000 | 6,534,000,000 | 5,803,000,000 | 4,676,000,000 | 3,125,000,000 | 61,000,000 | 130,000,000 | - | - | - |
| Operating Margin | 19.6% | 17.2% | 18.1% | 15.5% | 18.2% | 16.3% | 19.3% | 16.6% | 13.6% | 8.7% | 2.1% | 4.4% | - | - | - |
| % EBITDA Margin | 31.2% | 27.1% | 27.6% | 24.3% | 25.5% | 22.5% | 24.3% | 21.9% | 19.9% | 14.6% | 26.9% | 32.4% | - | - | - |
| NET Income (USD) | 5,721,000,000 | 5,934,000,000 | 5,136,000,000 | 3,875,000,000 | 4,509,000,000 | 4,388,000,000 | 4,800,000,000 | 8,555,000,000 | 4,410,000,000 | 2,837,000,000 | (136,000,000) | 59,000,000 | - | - | - |
| % Net Margin | 18.8% | 17.8% | 14.7% | 11.8% | 13.4% | 12.7% | 14.2% | 24.4% | 12.8% | 7.9% | (4.6%) | 2.0% | - | - | - |
Sanofi S.A. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Carve Out | Completed | Opella Healthcare Group SAS | - | ||||||||
| Add-on, Corporate Carve Out | Completed | Muscoril | - | ||||||||
| Add-on | Completed | Sanofi's anti-infective portfolio | - | ||||||||
| Add-on | Completed | Sanofi's Two Product Portfolios | - | ||||||||
| Add-on | Completed | 12 Sanofi Pharmaceutical Brands | - |
Displaying 1 - 5 of 13
Sanofi S.A. - employee data
Sanofi S.A. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM | ||||||
| President, Chief Medical Officer & Board Member | BM | ||||||
| Director, member of the board of Millchem | BM | ||||||
| Chairman of Board | BM | ||||||
| Member of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.